.Charles Baum, M.D., Ph.D., that oversaw Mirati Therapies' $ 5.8 billion purchase to Bristol Myers Squibb in 2013, is taking the reins of young biotech Terremoto Biosciences.Baum's "considerable expertise in medicine growth, and proven record in advancing high-impact medicines, will contribute," outward bound chief executive officer Peter Thompson, M.D., pointed out in a July 25 launch. Thompson will retain his seat as board chairperson..Baum, a trained physician-scientist, was the creator, president and CEO of oncology-focused Mirati. Just before that, he helped develop cancer cells medicines at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum is going to work as chief executive officer at Terremoto, a firm building little molecules to target disease-causing proteins-- like those located in malignant lump cells-- using covalent connects. Existing therapies that utilize covalent connections mostly target the amino acid cysteine. However, of the 20 amino acids that compose proteins, cysteine is actually the minimum usual. Terremoto is actually instead targeting one of the necessary amino acids, amino acid lysine, which is discovered in almost all proteins.Through targeting amino acid lysine and various other amino acids, Terremoto expects to manage formerly undruggable ailments and produce first-in-class medicines..The biotech, located in South San Francisco, increased $75 million in series A funding in 2022. A little much more than a year later, the biotech much more than doubled that variety in a $175 thousand collection B.